Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 3/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25090466 | 0.88 | ADORA2B (0.78) | ADORA2AADORA2BADORA1KDM4ECYP1A2 | |
| SCHEMBL6868854 | 0.87 | ADORA2B (0.76) | ADORA2AADORA2BADORA1KDM4ECYP1A2 | |
| SCHEMBL516013 | 0.87 | ADORA2B (0.77) | ADORA2AADORA2BADORA1KDM4ECYP1A2 | |
| SCHEMBL516029 | 0.85 | ADORA2B (0.75) | ADORA2AADORA2BADORA1KDM4ECYP1A2 | |
| SCHEMBL10723936 | 0.85 | ADORA2B (1.00) | ADORA2AADORA2BADORA1KDM4ECYP1A2 | |
| SCHEMBL7318169 | 0.85 | KDM4E (0.76) | ADORA2AADORA2BADORA1KDM4ECYP1A2 | |
| SCHEMBL515588 | 0.85 | KDM4E (0.76) | ADORA2AADORA2BADORA1KDM4ECYP1A2 | |
| SCHEMBL25090491 | 0.85 | ADORA2B (0.75) | ADORA2AADORA2BADORA1KDM4ECYP1A2 | |
| SCHEMBL25090657 | 0.85 | ADORA2B (0.73) | ADORA2AADORA2BADORA1KDM4ECYP1A2 | |
| SCHEMBL25090490 | 0.85 | ALDH1A1 (1.00) | ADORA2AADORA2BADORA1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | SAWYER MICHAEL BRUCE (CA) | 2026-03-17 | — | — | US | claimed |
| US-20230301968-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | ZEPHAPHARM LTD (GB) | 2023-09-28 | — | — | US | claimed |
| EP-3923936-B1 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | ZEPHAPHARM LTD (GB) | 2023-08-09 | — | — | EP | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-3972591-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | ZEPHAPHARM LTD (GB) | 2022-12-28 | — | — | EP | claimed |
| US-20220125765-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | ZEPHAPHARM LTD (GB) | 2022-04-28 | — | — | US | claimed |
| EP-3972591-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | Zephapharm Ltd. (GB) | 2022-03-30 | — | — | EP | claimed |
| WO-2022034275-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | ZEPHAPHARM LTD (GB) | 2022-02-17 | — | — | WO | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| EP-3923936-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING MEBENDAZOLE AND A STRONG OR MODERATE CYP1A2 INHIBITOR | Zephapharm Ltd. (GB) | 2021-12-22 | — | — | EP | claimed |
| WO-1991007945-A1 | UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR | LVMH RECHERCHE (FR) | 1991-06-13 | — | — | WO | claimed |
| EP-0322206-A2 | Compositions and methods for improving cold tolerance in animals and humans | HER MAJESTY IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) | 1989-06-28 | — | — | EP | claimed |
| EP-0167566-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | SUNSHINE ABRAHAM (US) | 1987-06-29 | — | — | EP | claimed |
| EP-0165308-A4 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1986-05-16 | — | — | EP | claimed |
| US-4567183-A | SYNERGISTIC, POTENTIATION | ANALGESIC ASSOCIATES (US) | 1986-01-28 | — | — | US | claimed |
| EP-0167566-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE, Abraham (US) | 1986-01-15 | — | — | EP | claimed |
| EP-0165308-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. | RICHARDSON VICKS INC (US) | 1985-12-27 | — | — | EP | claimed |
| US-4558051-A | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same | RICHARDSON-VICKS, INC. (US) | 1985-12-10 | — | — | US | claimed |
| WO-1985002540-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | RICHARDSON-VICKS, INC. (US) | 1985-06-20 | — | — | WO | claimed |
| WO-1985002542-A1 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME | SUNSHINE ABRAHAM | 1985-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576085-B2 | Combination comprising an ATP analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer | ADORA2A, ADORA2B, ABCG2 | ADORA2A 1/4885ADORA2B 2/4885ADORA1 9/4885 |
| US-20230301968-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE | CYP3A43, CYP1A2, CYP3A5 | ADORA2A 458/4885ADORA2B 267/4885ADORA1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.